Companies › Hangzhou Gensciences Biopharmaceutical
1 active drug program in 2 registered trials: 2 Phase 3; Hematology; next expected readout Feb 2027.
Open in Phaseline: competitors, likelihood bands and readouts Company report
| Drug | Target | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|
| FRSW107 Recombinant human coagulation Factor VIII-Fc fusion protein | F8 | Phase 3 | Severe Hemophilia A | Feb 2027 |
| Registry id | Drug | Phase | Conditions | Area | Expected readout |
|---|---|---|---|---|---|
| NCT07663903 | FRSW107 | Phase 3 | Severe Hemophilia A | Hematology | Feb 2027 |
| NCT07684898 | FRSW107 | Phase 3 | Severe Hemophilia A | Hematology | Mar 2027 |
Bioverativ, a Sanofi company Gritgen Therapeutics Forma Therapeutics Wuhan Createrna Science and Technology Pharmanutra
Pipelines of the same shape: areas, drug types, target families, stage and cash runway.
Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.